The Pro Medicus Limited (ASX: PME) share price has started the week in the red.
In afternoon trade, the health imaging technology company’s shares are down slightly to $45.50.
This means the Pro Medicus share price is now down 28% since the start of the year.
Is the Pro Medicus share price good value?
One leading broker that sees a lot of value in the Pro Medicus share price is Bell Potter.
According to a note, the broker has upgraded the company’s shares to a buy rating with a trimmed price target of $55.00.
Based on the current Pro Medicus share price, this implies potential upside of 21% over the next 12 months.
What did the broker say?
Bell Potter made the move on valuation grounds. It believes the “recent route in high growth technology and healthcare stocks has created an attractive entry point for some high quality names including PME.”
Particularly given its expectation for Pro Medicus to deliver double digit revenue and earnings growth later this month when it releases its half year results.
In addition, the broker is positive on the future and believes that “as imaging technology grows in complexity (and data size) the use case for the Visage technology continues to become more compelling.”
And while Morgans has trimmed its price target, it feels this is appropriate following the recent market selloff and notes that it still offers major upside potential.
The broker explained: “Our target price is amended to $55.00 from $62.00. The target price is determined from a hybrid model of a DCF and a capitalised earnings model. We applied a 10% discount to the capitalisation multiple of revenues in order to adjust the target price. In our view this is appropriate following the recent market correction across both healthcare and information technology sectors.”
“In our view the current market price represents an attractive entry point to this very high quality healthcare technology play. We upgrade our recommendation from Hold to Buy. Changes to earnings are not material,” it concluded.
The post Leading broker says Pro Medicus (ASX:PME) share price is a buy appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you consider Pro Medicus, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- 2 medical tech ASX shares for turbulent times
- 5 things to watch on the ASX 200 on Monday
- These were the worst performing ASX 200 shares in January
- Leading brokers name 3 ASX shares to buy today
- Why this broker upgraded the embattled Pro Medicus (ASX:PME) share price to “buy”
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/R6DvFEY
Leave a Reply